JPRN-UMIN000004811招募中2 期
mFOLFOX6+Cetuximab in Treating Patients With not Optimally Resectable Liver Metastases From Colorectal Cancer - mFOLFOX6+Cetuximab in Treating Patients With not Optimally Resectable Liver Metastases From Colorectal Cancer
Cancer Institute Hospital of Japanese Foundation for Cancer Research0 个研究点目标入组 45 人开始时间: 2011年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) No severe heart disease 2) No past history of AMI within 6 months 3) Not pregnant 4) Uncontrolled infectious disease 5) No systemic steroids or immunosupressant 6) No severe drug allergy 7) No psychological, familial, social, or geographical condition that would preclude study compliance 8) No symptomatic effusion collection 9) No severe peripheral neuropathy 10) No watery diarrhea 11) No other significant disease that would preclude study participationr
研究者
相似试验
招募中
2 期
Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancerRectal CancerJPRN-UMIN000010791PO FMPC (Future Medicine Promoting Consortium)25
进行中（未招募）
1 期
Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status - CEBIFOXEUCTR2007-000460-24-DEniversity of Duisburg-Essen
Unknown
2 期
Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer PatientsLiver MetastasesColorectal CancerNCT01322178Fudan University90
已完成
1 期
Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancerRAS wild-type unresectable colorectal cancerJPRN-UMIN000015620Aichi Cancer Center Hospital12
已完成
2 期
Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancernresectable hepatic metastasis of colorectal cancerJPRN-UMIN000004310Kyoto University35